vigabatrin has been researched along with Day Blindness in 133 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Interim analysis of three groups with refractory partial epilepsy, stratified by age (8-12 years; >12 years) and exposure to vigabatrin (VGB)." | 7.74 | Vigabatrin and epilepsy: lessons learned. ( Ahn, HS; Baulac, M; Bursztyn, J; Chiron, C; Gandolfo, E; Perucca, E; Safran, AB; Schiefer, U; Wild, JM, 2007) |
| "Visual field constriction (VFC) occurs in approximately 40 % of epilepsy patients under treatment with vigabatrin (VGB)." | 7.71 | Is visual field constriction in epilepsy patients treated with vigabatrin reversible? ( Jokiel, B; Pfeiffer, S; Rüther, K; Schmidt, T; Schmitz, B; Tiel-Wilck, K, 2002) |
| "Vigabatrin (VGB) is a new antiepileptic drug, that acts by the irreversible inhibition of gamma-aminobutyric acid (GABA) aminotransferase." | 6.42 | [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy]. ( Bakunowicz-Łazarczyk, A; Mrugacz, M, 2003) |
| "Vigabatrin is an anti-epileptic drug particularly useful for drug-resistant partial seizures and infantile spasms." | 5.31 | Visual impairment in children with epilepsy treated with vigabatrin. ( Banin, E; Gross-Tsur, V; Lahat, E; Shahar, E; Shalev, RS, 2000) |
| "The aim of the study was to assess the prevalence of visual field constriction in a consecutive, unselected series of patients in the Copenhagen area treated with vigabatrin for severe epilepsy, and further to assess appropriate screening techniques for detecting such visual field defects." | 5.10 | [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods]. ( Fledelius, HC; Riise, P; Rogvi-Hansen, Bà, 2003) |
| " The staging of the loss could assist the risk:benefit analysis of vigabatrin for the treatment of epilepsy." | 3.91 | Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy. ( Knupp, C; Smith, PEM; Wild, JM, 2019) |
| "Subjects were older than 18 years, 129 with vigabatrin-treated epilepsy (vigabatrin-exposed group) and 87 individuals with epilepsy never treated with vigabatrin (nonexposed group)." | 3.78 | Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals. ( Acheson, JF; Clayton, LM; de Haan, GJ; Devile, M; Punte, T; Sander, JW; Sisodiya, SM, 2012) |
| "Interim analysis of three groups with refractory partial epilepsy, stratified by age (8-12 years; >12 years) and exposure to vigabatrin (VGB)." | 3.74 | Vigabatrin and epilepsy: lessons learned. ( Ahn, HS; Baulac, M; Bursztyn, J; Chiron, C; Gandolfo, E; Perucca, E; Safran, AB; Schiefer, U; Wild, JM, 2007) |
| "The utility of vigabatrin in the treatment of epilepsy is partially offset by its retinal toxicity." | 3.72 | Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. ( Frisén, L, 2004) |
| "To evaluate through a longitudinal study the effects on visual fields of long-term vigabatrin medication in patients with partial epilepsy and to discuss visual field screening strategies." | 3.72 | Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. ( Fledelius, HC, 2003) |
| "Six patients with epilepsy treated with vigabatrin as add-on therapy for at least 3 years were included in this observational case series." | 3.72 | Retinal function abnormalities in patients treated with vigabatrin. ( Banin, E; Chowers, I; Gross-Tsur, V; Neis, R; Obolensky, A; Shalev, RS, 2003) |
| "We described course of disease of a 12 year old boy with epilepsy, treated with vigabatrin." | 3.72 | [Changes in visual field of a child treatment with vigabatrin for 2 years]. ( Bakunowicz-Łazarczyk, A; Mrugacz, M, 2003) |
| "Vigabatrin use in some epilepsy patients has been associated with persistent visual field constriction and retinal dysfunction." | 3.71 | GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects. ( Felice, K; Hisama, FM; Lee, HH; Mattson, RH; Petroff, OA, 2001) |
| "To describe the correlation between visual field loss and the duration, dosage, and total amount of vigabatrin (VGB) medication in a group of patients with epilepsy." | 3.71 | Visual field loss associated with vigabatrin: quantification and relation to dosage. ( Berendschot, TT; Edelbroek, PM; Engelsman, M; Hardus, P; Segers, JP; Stilma, JS; Verduin, WM, 2001) |
| "Visual field constriction (VFC) occurs in approximately 40 % of epilepsy patients under treatment with vigabatrin (VGB)." | 3.71 | Is visual field constriction in epilepsy patients treated with vigabatrin reversible? ( Jokiel, B; Pfeiffer, S; Rüther, K; Schmidt, T; Schmitz, B; Tiel-Wilck, K, 2002) |
| " Treatment of epilepsy with vigabatrin (VGB) exemplifies these problems." | 3.71 | Adverse events in medical management--vigabatrin as a paradigm of forensic responsibility with novel therapy. ( Beran, RG, 2001) |
| "Vigabatrin (Sabril), a drug that blocks GABA transaminase, has been used in the treatment of epilepsy since 1989." | 3.70 | Vigabatrin-associated visual field defects in children. ( Mackey, DA; Russell-Eggitt, IM; Taylor, DS; Timms, C; Walker, JW, 2000) |
| "21 consecutive patients who had taken vigabatrin at some time in their lives were enrolled from the epilepsy clinic of the Royal Shrewsbury Hospital and were compared with a group of 11 otherwise similar patients with epilepsy who had never received vigabatrin." | 3.70 | A controlled study of vigabatrin and visual abnormalities. ( Goodman, S; Manuchehri, K; Nightingale, S; Siviter, L, 2000) |
| "Vigabatrin can cause retinopathy, resulting in bilateral visual field constriction." | 2.75 | Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy. ( Bittman, RM; Christen, EM; Sagar, SM; Sergott, RC, 2010) |
| "734 patients with refractory partial epilepsy, divided into three groups and stratified by age (8-12 years; >12 years) and exposure to vigabatrin." | 2.74 | Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. ( Ahn, H; Baulac, M; Bursztyn, J; Chiron, C; Gandolfo, E; Goldberg, I; Goñi, FJ; Mercier, F; Nordmann, JP; Perucca, E; Safran, AB; Schiefer, U; Wild, JM, 2009) |
| "Vigabatrin (VGB) has been shown to cause visual field constriction and other forms of mild visual dysfunction." | 2.70 | Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making. ( Johnson, MA; Krauss, GL; Medura, MT; Miller, NR; Miller, TA; Paul, SR, 2001) |
| "The majority of these people have focal epilepsy." | 2.66 | Vigabatrin add-on therapy for drug-resistant focal epilepsy. ( Bresnahan, R; Gianatsi, M; Maguire, MJ; Marson, AG; Tudur Smith, C, 2020) |
| "Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid (GABA) transaminase." | 2.47 | Understanding and interpreting vision safety issues with vigabatrin therapy. ( Plant, GT; Sergott, RC, 2011) |
| " Its efficacy in achieving improved seizure control should be apparent within 12 weeks in patients with rCPS and within 2-4 weeks after attaining appropriate dosage for patients with IS." | 2.47 | Balancing clinical benefits of vigabatrin with its associated risk of vision loss. ( Pellock, JM, 2011) |
| "Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractory epilepsy and used in infantile spasms." | 2.46 | Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. ( Hemming, K; Hutton, JL; Maguire, MJ; Marson, AG; Wild, JM, 2010) |
| "Vigabatrin (Sabril) was approved in the USA in mid-2009 for the adjunctive treatment of refractory complex partial seizures and as treatment of infantile spasms." | 2.45 | Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. ( Faulkner, MA; Tolman, JA, 2009) |
| "Vigabatrin has been shown to be a generally well tolerated and effective antiepileptic drug (AED) in a wide variety of seizure types affecting both children and adults, particularly those with IS and CPS." | 2.44 | Vigabatrin. ( Collins, SD; Ramsay, RE; Wheless, JW, 2007) |
| "Vigabatrin (VGB) is a new antiepileptic drug, that acts by the irreversible inhibition of gamma-aminobutyric acid (GABA) aminotransferase." | 2.42 | [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy]. ( Bakunowicz-Łazarczyk, A; Mrugacz, M, 2003) |
| "Vigabatrin is a GABA (gamma-aminobutyric acid) transaminase inhibitor that elicits an antiepileptic effect by enhancing inhibitory neurotransmission in the brain." | 2.41 | Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance. ( Hilton, EJ; Hosking, SL, 2002) |
| "Vigabatrin is an antiepileptic drug (AED) that acts as a selective irreversible inhibitor of gamma-aminobutyric acid (GABA) transaminase." | 2.41 | Visual field defects with vigabatrin: epidemiology and therapeutic implications. ( Kälviäinen, R; Nousiainen, I, 2001) |
| "Vigabatrin toxicity was defined as the presence of VAVFL." | 1.51 | The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to Vigabatrin. ( Aljarudi, S; Knupp, C; Smith, PEM; Wild, JM, 2019) |
| "VGB is effective in treating infantile spasms, a rare seizure disorder associated with significant morbidity." | 1.46 | Aberrant mTOR signaling and disrupted autophagy: The missing link in potential vigabatrin-associated ocular toxicity? ( Ainslie, GR; Gibson, KM; Pearl, PL; Vogel, KR, 2017) |
| "Vigabatrin (Sabril®) is an antiepileptic drug (AED) currently indicated in the US as a monotherapy for patients 1month to 2years of age with infantile spasms (IS) and as adjunctive therapy for patients ≥10years of age with refractory complex partial seizures (rCPS) whose seizures have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss." | 1.43 | Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. ( Dribinsky, Y; Faught, E; Foroozan, R; Isojarvi, J; Lee, D; Othman, F; Pellock, JM; Sergott, RC; Shields, WD; Torri, S; Ziemann, A, 2016) |
| "In the treatment of infantile spasms, risk-benefit assessment should consider both the low prevalence of ERG-identified VAVFL among patients with brief (<6-9months) exposure and the very low prevalence of clinically apparent VAVFL in this population." | 1.43 | A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. ( Hussain, SA; Li, M; Sankar, R; Schwarz, MD; Tsao, J; Wu, JY; Wu, YW; Zhou, R, 2016) |
| "Vigabatrin (VGB) is an anti-epileptic medication which has been linked to peripheral constriction of the visual field." | 1.40 | Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin? ( Conway, ML; Cubbidge, RP; Hosking, SL; Zhu, H, 2014) |
| "Nine individuals with partial epilepsy and VGB-attributed visual field loss (group 1; 18 eyes) and seven age- and gender-matched individuals with epilepsy and no previous VGB exposure (group 2; 14 eyes) were included in the study." | 1.37 | Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. ( Brodtkorb, E; Gajda, A; Hoff, JM; Midelfart, A; Moseng, L; Mørch-Johnsen, GH; Sæter, M, 2011) |
| " The effects of the following factors on contrast sensitivity and visual acuity were examined: type of seizure (infantile spasms versus other), ERG result, duration of vigabatrin therapy, cumulative dosage of vigabatrin, and other seizure medications (other versus no other medication)." | 1.33 | Reduced visual function associated with infantile spasms in children on vigabatrin therapy. ( Buncic, JR; Hammoudi, DS; Lee, SS; Logan, WJ; Madison, A; Mirabella, G; Snead, OC; Westall, CA, 2005) |
| "Vigabatrin (VGB) is an important treatment option for infantile spasms." | 1.33 | Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero. ( Heinonen, S; Herrgård, E; Kälviäinen, R; Pääkkönen, A; Sorri, I; Viinikainen, K, 2005) |
| "Vigabatrin (VGB) is an irreversible inhibitor of gamma-aminobutyric acid (GABA) transaminase." | 1.32 | Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA. ( Benz, AM; Ishikawa, M; Izumi, M; Izumi, Y; Thio, LL; Zorumski, CF, 2004) |
| "Vigabatrin (GVG) is an effective antiepileptic drug used for treating partial seizures in adults and children." | 1.32 | Visual field defects in pediatric patients on vigabatrin monotherapy. ( Ascaso, FJ; Cristobal, JA; Lopez, MJ; Mauri, JA, 2003) |
| "Vigabatrin is an effective antiepileptic drug, but it is known to cause a variety of changes in visual function, including reductions in the visual field, visual acuity, color vision, and in electroretinogram (ERG) and electro-oculogram amplitudes." | 1.31 | Visual function loss from vigabatrin: effect of stopping the drug. ( Johnson, MA; Krauss, GL; Medura, M; Miller, NR; Paul, SR, 2000) |
| "Vigabatrin is an anti-epileptic drug particularly useful for drug-resistant partial seizures and infantile spasms." | 1.31 | Visual impairment in children with epilepsy treated with vigabatrin. ( Banin, E; Gross-Tsur, V; Lahat, E; Shahar, E; Shalev, RS, 2000) |
| "Doctors should advise patients of recognised adverse events of proposed therapy." | 1.31 | Ethical dilemmas of potential adverse events. ( Beran, RG, 2001) |
| "Vigabatrin is an extremely effective antiepileptic drug that selectively increases brain gamma-aminobutyric acid (GABA)." | 1.30 | Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. ( Johnson, MA; Krauss, GL; Miller, NR, 1998) |
| "Vigabatrin can cause electrophysiologic evidence of retinal dysfunction and clinically detectable disturbances of visual sensory function." | 1.30 | Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. ( Endres, M; Girkin, CA; Johnson, MA; Krauss, GL; Miller, NR; Paul, SR; Perry, JD, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (17.29) | 18.2507 |
| 2000's | 78 (58.65) | 29.6817 |
| 2010's | 31 (23.31) | 24.3611 |
| 2020's | 1 (0.75) | 2.80 |
| Authors | Studies |
|---|---|
| Bresnahan, R | 1 |
| Gianatsi, M | 1 |
| Maguire, MJ | 2 |
| Tudur Smith, C | 1 |
| Marson, AG | 3 |
| Androsova, G | 1 |
| Krause, R | 1 |
| Borghei, M | 1 |
| Wassenaar, M | 1 |
| Auce, P | 1 |
| Avbersek, A | 1 |
| Becker, F | 1 |
| Berghuis, B | 1 |
| Campbell, E | 1 |
| Coppola, A | 1 |
| Francis, B | 1 |
| Wolking, S | 1 |
| Cavalleri, GL | 1 |
| Craig, J | 1 |
| Delanty, N | 1 |
| Koeleman, BPC | 1 |
| Kunz, WS | 1 |
| Lerche, H | 1 |
| Sander, JW | 4 |
| Sills, GJ | 3 |
| Striano, P | 1 |
| Zara, F | 1 |
| Sisodiya, SM | 3 |
| Depondt, C | 1 |
| Wild, JM | 9 |
| Aljarudi, S | 1 |
| Smith, PEM | 2 |
| Knupp, C | 2 |
| Ji, X | 1 |
| McFarlane, M | 1 |
| Liu, H | 1 |
| Dupuis, A | 1 |
| Westall, CA | 6 |
| Chiron, C | 4 |
| Dulac, O | 2 |
| Riikonen, R | 1 |
| Rener-Primec, Z | 1 |
| Carmant, L | 2 |
| Dorofeeva, M | 1 |
| Hollody, K | 1 |
| Szabo, I | 1 |
| Krajnc, BS | 1 |
| Wohlrab, G | 1 |
| Sorri, I | 3 |
| Conway, ML | 1 |
| Hosking, SL | 4 |
| Zhu, H | 1 |
| Cubbidge, RP | 3 |
| Krauss, G | 1 |
| Faught, E | 3 |
| Foroozan, R | 3 |
| Pellock, JM | 4 |
| Sergott, RC | 8 |
| Shields, WD | 3 |
| Ziemann, A | 2 |
| Dribinsky, Y | 2 |
| Lee, D | 3 |
| Torri, S | 2 |
| Othman, F | 2 |
| Isojarvi, J | 3 |
| Schwarz, MD | 1 |
| Li, M | 1 |
| Tsao, J | 1 |
| Zhou, R | 1 |
| Wu, YW | 1 |
| Sankar, R | 1 |
| Wu, JY | 1 |
| Hussain, SA | 1 |
| Hébert-Lalonde, N | 1 |
| Major, P | 1 |
| Roy, MS | 1 |
| Lassonde, M | 1 |
| Saint-Amour, D | 1 |
| Johnson, CA | 1 |
| Laxer, KD | 1 |
| Wechsler, RT | 1 |
| Cherny, K | 1 |
| Whittle, J | 1 |
| Feng, G | 1 |
| Vogel, KR | 1 |
| Ainslie, GR | 1 |
| Pearl, PL | 1 |
| Gibson, KM | 1 |
| Lawthom, C | 1 |
| Smith, PE | 2 |
| Durbin, S | 1 |
| Mirabella, G | 3 |
| Buncic, JR | 4 |
| Clayton, LM | 2 |
| Duncan, JS | 1 |
| Acheson, JF | 4 |
| Gonzalez, P | 1 |
| Parks, S | 1 |
| Kelly, K | 1 |
| Stephen, LJ | 1 |
| Keating, D | 1 |
| Dutton, GN | 1 |
| Brodie, MJ | 3 |
| Ahn, H | 2 |
| Baulac, M | 2 |
| Bursztyn, J | 2 |
| Gandolfo, E | 3 |
| Goldberg, I | 1 |
| Goñi, FJ | 1 |
| Mercier, F | 1 |
| Nordmann, JP | 1 |
| Safran, AB | 2 |
| Schiefer, U | 3 |
| Perucca, E | 2 |
| Brady, KT | 1 |
| Tolman, JA | 1 |
| Faulkner, MA | 1 |
| Ibrahim, S | 1 |
| Gulab, S | 1 |
| Ishaque, S | 1 |
| Saleem, T | 1 |
| Besag, FM | 1 |
| Gaily, E | 1 |
| Jonsson, H | 1 |
| Lappi, M | 1 |
| Bittman, RM | 1 |
| Christen, EM | 1 |
| Sagar, SM | 1 |
| Hemming, K | 1 |
| Hutton, JL | 1 |
| Moseng, L | 1 |
| Sæter, M | 1 |
| Mørch-Johnsen, GH | 1 |
| Hoff, JM | 1 |
| Gajda, A | 1 |
| Brodtkorb, E | 2 |
| Midelfart, A | 3 |
| Besch, D | 1 |
| Eter, N | 1 |
| Burth, R | 1 |
| Elger, CE | 1 |
| Spitznas, M | 1 |
| Dietz, K | 1 |
| Burkhart, GA | 1 |
| Krauss, GL | 6 |
| Wesche, DL | 1 |
| Weinberg, MA | 1 |
| Plant, GT | 1 |
| Good, WV | 1 |
| Fecarotta, C | 1 |
| Hopkins, CR | 1 |
| Devile, M | 1 |
| Punte, T | 1 |
| de Haan, GJ | 1 |
| Kjellström, U | 2 |
| Andréasson, S | 3 |
| Ponjavic, V | 3 |
| Olson, JA | 1 |
| Purdie, AT | 1 |
| Coleman, RJ | 1 |
| Newman, WD | 1 |
| Tocher, K | 1 |
| Schmidt, T | 3 |
| Rüther, K | 3 |
| Jokiel, B | 2 |
| Pfeiffer, S | 2 |
| Tiel-Wilck, K | 2 |
| Schmitz, B | 4 |
| Hilton, EJ | 2 |
| Betts, T | 1 |
| Comaish, IF | 2 |
| Asensio Sánchez, VM | 1 |
| Fledelius, HC | 2 |
| Riise, P | 1 |
| Rogvi-Hansen, Bà | 1 |
| Harding, GF | 7 |
| Robertson, KA | 2 |
| Holliday, I | 2 |
| Banin, E | 3 |
| Shalev, RS | 2 |
| Obolensky, A | 1 |
| Neis, R | 1 |
| Chowers, I | 1 |
| Gross-Tsur, V | 3 |
| Hardus, P | 4 |
| Verduin, W | 1 |
| Berendschot, T | 1 |
| Postma, G | 3 |
| Stilma, J | 1 |
| van Veelen, C | 1 |
| Papadeas, E | 1 |
| Polychronopoulos, P | 1 |
| Papathanasopoulos, P | 1 |
| Frimas, C | 1 |
| Pharmakakis, N | 1 |
| Paschalis, C | 1 |
| Ascaso, FJ | 1 |
| Lopez, MJ | 1 |
| Mauri, JA | 1 |
| Cristobal, JA | 1 |
| Spencer, EL | 2 |
| Morong, S | 2 |
| Nobile, R | 1 |
| Logan, WJ | 3 |
| Panton, CM | 1 |
| Abdolell, M | 2 |
| Frisén, L | 2 |
| Mrugacz, M | 2 |
| Bakunowicz-Łazarczyk, A | 2 |
| Best, JL | 1 |
| Izumi, Y | 1 |
| Ishikawa, M | 1 |
| Benz, AM | 1 |
| Izumi, M | 1 |
| Zorumski, CF | 1 |
| Thio, LL | 1 |
| Choi, HJ | 1 |
| Kim, DM | 1 |
| Hammoudi, DS | 1 |
| Lee, SS | 1 |
| Madison, A | 1 |
| Snead, OC | 2 |
| Herrgård, E | 1 |
| Viinikainen, K | 1 |
| Pääkkönen, A | 1 |
| Heinonen, S | 1 |
| Kälviäinen, R | 2 |
| Mennel, S | 1 |
| Schulze, S | 1 |
| Meyer, CH | 1 |
| Kumar, N | 1 |
| Jivan, S | 1 |
| Moreno, MC | 1 |
| Giagante, B | 1 |
| Saidon, P | 1 |
| Kochen, S | 1 |
| Benozzi, J | 1 |
| Rosenstein, RE | 1 |
| Robson, CR | 1 |
| Jones, AL | 1 |
| Cunliffe, IA | 1 |
| Pojda-Wilczek, D | 1 |
| Emich-Widera, E | 1 |
| Herba, E | 1 |
| Pojda, SM | 1 |
| Marszał, E | 1 |
| Werth, R | 1 |
| Schädler, G | 1 |
| You, SJ | 1 |
| Ko, TS | 1 |
| Wheless, JW | 1 |
| Ramsay, RE | 1 |
| Collins, SD | 1 |
| Durnian, JM | 1 |
| Clearkin, LG | 1 |
| Ahn, HS | 1 |
| Weiss, SK | 1 |
| Depasse, F | 1 |
| Conway, M | 1 |
| Parisi, P | 1 |
| Bombardieri, R | 1 |
| Curatolo, P | 1 |
| Lövestam-Adrian, M | 1 |
| Hawker, MJ | 1 |
| Astbury, NJ | 1 |
| Eke, T | 1 |
| Talbot, JF | 1 |
| Lawden, MC | 2 |
| Wilson, EA | 1 |
| Wong, IC | 1 |
| Mawer, GE | 1 |
| Blackwell, N | 1 |
| Hayllar, J | 1 |
| Kelly, G | 1 |
| Backstrom, JT | 1 |
| Hinkle, RL | 1 |
| Flicker, MR | 1 |
| Mackenzie, R | 1 |
| Klistorner, A | 1 |
| Johnson, MA | 4 |
| Miller, NR | 5 |
| Ruether, K | 1 |
| Pung, T | 1 |
| Kellner, U | 1 |
| Hartmann, C | 1 |
| Seeliger, M | 1 |
| Rao, GP | 1 |
| Fat, FA | 1 |
| Kyle, G | 1 |
| Leach, JP | 1 |
| Chadwick, DW | 1 |
| Batterbury, M | 1 |
| Appleton, RE | 1 |
| Beck, RW | 1 |
| Brigell, MG | 1 |
| Roubertie, A | 1 |
| Bellet, H | 1 |
| Echenne, B | 1 |
| Lhatoo, SD | 1 |
| Stefan, H | 1 |
| Bernatik, J | 1 |
| Knorr, J | 1 |
| Roubergue, A | 1 |
| Pelosse, B | 1 |
| Doummar, D | 1 |
| Beauvais, P | 1 |
| Montchilova, M | 1 |
| Gonthier, B | 1 |
| Billette de Villemeur, T | 1 |
| Daneshvar, H | 1 |
| Racette, L | 1 |
| Coupland, SG | 1 |
| Kertes, PJ | 1 |
| Guberman, A | 1 |
| Zackon, D | 1 |
| Wilton, LV | 1 |
| Stephens, MD | 1 |
| Mann, RD | 1 |
| Paul, SR | 3 |
| Girkin, CA | 1 |
| Perry, JD | 1 |
| Endres, M | 1 |
| Martinez, C | 1 |
| Reinshagen, G | 1 |
| Manuchehri, K | 2 |
| Goodman, S | 1 |
| Siviter, L | 1 |
| Nightingale, S | 1 |
| Verduin, WM | 3 |
| Stilma, JS | 3 |
| Berendschot, TT | 3 |
| van Veelen, CW | 2 |
| Gorman, C | 1 |
| Galloway, NR | 1 |
| Rebolleda, G | 1 |
| Muñoz-Negrete, FJ | 1 |
| Gutierrez, C | 1 |
| Medura, M | 1 |
| Shahar, E | 2 |
| Lahat, E | 2 |
| Russell-Eggitt, IM | 1 |
| Mackey, DA | 1 |
| Taylor, DS | 1 |
| Timms, C | 1 |
| Walker, JW | 1 |
| Midelfart, E | 1 |
| Giordano, L | 1 |
| Valseriati, D | 1 |
| Vignoli, A | 1 |
| Morescalchi, F | 1 |
| Betts, TA | 1 |
| Barber, C | 1 |
| Barnes, PM | 1 |
| Luchetti, A | 1 |
| Amadi, A | 1 |
| Gobbi, G | 1 |
| Prasad, AN | 1 |
| Penney, S | 1 |
| Buckley, DJ | 1 |
| Engelsman, M | 1 |
| Edelbroek, PM | 1 |
| Segers, JP | 1 |
| Kamermans, M | 1 |
| Jensen, K | 1 |
| Malmgren, K | 1 |
| Ben-Menachem, E | 1 |
| Medura, MT | 1 |
| Miller, TA | 1 |
| Nousiainen, I | 2 |
| Patsalos, PN | 1 |
| Butler, E | 1 |
| Forrest, G | 1 |
| Ratnaraj, N | 1 |
| Beran, RG | 2 |
| Hisama, FM | 1 |
| Mattson, RH | 1 |
| Lee, HH | 1 |
| Felice, K | 1 |
| Petroff, OA | 1 |
| Shalev, R | 1 |
| Robertson, K | 1 |
| Vanhatalo, S | 1 |
| Eriksson, K | 1 |
| Rantala, H | 1 |
| Vainionpää, L | 1 |
| Mustonen, K | 1 |
| Aärimaa, T | 1 |
| Alen, R | 1 |
| Aine, MR | 1 |
| Byring, R | 1 |
| Hirvasniemi, A | 1 |
| Nuutila, A | 1 |
| Walden, T | 1 |
| Ritanen-Mohammed, UM | 1 |
| Karttunen-Lewandowski, P | 1 |
| Pohjola, LM | 1 |
| Kaksonen, S | 1 |
| Jurvelin, P | 1 |
| Granström, ML | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Vigabatrin With High Dose Prednisolone Combination Therapy Versus Vigabatrin Alone for Infantile Spasm: a Randomized Trial[NCT04302116] | 250 participants (Anticipated) | Interventional | 2020-05-18 | Recruiting | |||
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for vigabatrin and Day Blindness
| Article | Year |
|---|---|
Vigabatrin add-on therapy for drug-resistant focal epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dizziness; Drug Resistant Epilepsy; Drug Therapy, Combina | 2020 |
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.
Topics: Adult; Animals; Anticonvulsants; Drug Approval; Epilepsy, Complex Partial; Humans; Infant; Middle Ag | 2009 |
Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
Topics: Adult; Anticonvulsants; Child; Drug Resistance; Epilepsies, Partial; Female; Humans; Male; Prevalenc | 2010 |
Understanding and interpreting vision safety issues with vigabatrin therapy.
Topics: 4-Aminobutyrate Transaminase; Adult; Animals; Anticonvulsants; Causality; Comorbidity; Confounding F | 2011 |
Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
Topics: Adult; Anticonvulsants; Electroretinography; Epilepsies, Partial; GABA Agents; Humans; Infant; Spasm | 2011 |
Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
Topics: Adult; Animals; Anticonvulsants; Child; Epilepsies, Partial; Humans; Infant; Magnetic Resonance Imag | 2011 |
Vigabatrin-associated visual field loss.
Topics: Adult; Anticonvulsants; Child, Preschool; GABA Agents; Humans; Infant; Vigabatrin; Vision Disorders; | 2012 |
ACS chemical neuroscience molecule spotlight on Sabril.
Topics: 4-Aminobutyrate Transaminase; Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Enzyme | 2010 |
Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance.
Topics: 4-Aminobutyrate Transaminase; Electroretinography; Enzyme Inhibitors; Epilepsy; Eye; Humans; Regiona | 2002 |
[Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2003 |
Vigabatrin.
Topics: Animals; Anticonvulsants; Brain; Clinical Trials as Topic; Epilepsy; Humans; Risk Assessment; Vigaba | 2007 |
[Epilepsy and Sabril].
Topics: Adult; Algorithms; Animals; Anticonvulsants; Child; Epilepsy; Humans; Optic Nerve Diseases; Retinal | 2007 |
Visual field defects with vigabatrin: epidemiology and therapeutic implications.
Topics: Animals; Anticonvulsants; Evoked Potentials, Visual; Humans; Vigabatrin; Vision Disorders; Visual Fi | 2001 |
Vigabatrin; its effect on the electrophysiology of vision.
Topics: Anticonvulsants; Electrooculography; Electroretinography; Humans; Vigabatrin; Vision Disorders; Visi | 2002 |
8 trials available for vigabatrin and Day Blindness
| Article | Year |
|---|---|
Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
Topics: Adult; Anticonvulsants; Epilepsy, Complex Partial; Female; Humans; Longitudinal Studies; Male; Nerve | 2016 |
Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Drug Monitoring; Epilepsies, Partial; | 2009 |
Clinical profile and treatment of infantile spasms using vigabatrin and ACTH--a developing country perspective.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Asphyxia Neonatorum; Cerebral Palsy; Developing Countr | 2010 |
Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
Topics: Anticonvulsants; Child; Epilepsies, Partial; Female; Follow-Up Studies; Humans; International Cooper | 2010 |
[Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Humans; Middle Aged; Predictive Value of Tests; | 2003 |
Contrast sensitivity is reduced in children with infantile spasms.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Contrast Sensitivity; Cross-Sectional Studies; | 2007 |
[Visual field defects due to antiepileptic drugs].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dr | 1999 |
Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
Topics: Adult; Aged; Anticonvulsants; Color Vision Defects; Drug Administration Schedule; Epilepsy; Female; | 2001 |
111 other studies available for vigabatrin and Day Blindness
| Article | Year |
|---|---|
Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Ataxia; Benzodiazepines; Carbamazepine; Clobazam; | 2017 |
The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to Vigabatrin.
Topics: Adult; Anticonvulsants; Cohort Studies; Cross-Sectional Studies; Dose-Response Relationship, Drug; F | 2019 |
Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin.
Topics: Anticonvulsants; Child, Preschool; Electroretinography; Epilepsy; Female; Humans; Infant; Male; Phot | 2019 |
Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.
Topics: Adult; Anticonvulsants; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Retrospective Studi | 2019 |
Analysis of vigabatrin treatment causing visual field defects in infantile spasms.
Topics: Anticonvulsants; Female; Humans; Male; Spasms, Infantile; Vigabatrin; Vision Disorders; Visual Field | 2015 |
Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Female; Humans; Infant; | 2015 |
Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?
Topics: Adolescent; Adult; Algorithms; Anticonvulsants; Female; Glaucoma; Humans; Male; Middle Aged; Sensiti | 2014 |
Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Epilepsy; Female; Humans; Kaplan-Meier | 2016 |
A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
Topics: Anticonvulsants; California; Child; Child, Preschool; Cohort Studies; Electroencephalography; Female | 2016 |
Electrophysiological Evidences of Visual Field Alterations in Children Exposed to Vigabatrin Early in Life.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Electroretinography; E | 2016 |
Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Complex Partial; Female; Humans; Infant; Male; Registr | 2016 |
Aberrant mTOR signaling and disrupted autophagy: The missing link in potential vigabatrin-associated ocular toxicity?
Topics: Anticonvulsants; Autophagy; Evoked Potentials, Visual; gamma-Aminobutyric Acid; Humans; Infant; Infa | 2017 |
Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Axons; Biomarkers; Carbamazepine; Cross-Sectional Studies; | 2009 |
Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.
Topics: Anticonvulsants; Child; Child, Preschool; Contrast Sensitivity; Evoked Potentials, Visual; Female; H | 2009 |
Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Retina; Retinal Ganglion Cells; Time Factors; Tomo | 2010 |
Binasal visual field defects are not specific to vigabatrin.
Topics: Adult; Anticonvulsants; Chi-Square Distribution; Electrooculography; Epilepsy; Female; Humans; Male; | 2009 |
Expanding treatment options for cocaine dependence.
Topics: Adult; Alcoholism; Animals; Cocaine-Related Disorders; Disease Models, Animal; Drug Approval; Drug-R | 2009 |
Vigabatrin: an antiepileptic drug with major benefits but significant adverse effects.
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Infant; Spasms, Infantile; Vigabatrin; Vision Disorders; V | 2010 |
Visual fields in children exposed to vigabatrin in infancy.
Topics: Age Factors; Child; Humans; Infant; Vigabatrin; Vision Disorders; Visual Fields | 2010 |
Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
Topics: Adult; Anticonvulsants; Epilepsies, Partial; Female; Follow-Up Studies; Humans; Male; Middle Aged; N | 2011 |
Epilepsy: Vigabatrin treatment and visual field loss.
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2011 |
Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Cross-Sectional Studies; Epilepsies, Partial; Femal | 2011 |
Registry initiated to characterize vision loss associated with vigabatrin therapy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Hu | 2011 |
Measuring field loss in children administered vigabatrin: a problem in search of a solution.
Topics: Anticonvulsants; Child; Humans; Infant; Spasms, Infantile; Time Factors; Vigabatrin; Vision Disorder | 2011 |
Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals.
Topics: Adult; Anticonvulsants; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Middle Aged; Nerve | 2012 |
Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication.
Topics: Adult; Aged; Anticonvulsants; Electroretinography; Female; Humans; Male; Middle Aged; Nerve Fibers; | 2014 |
Tangent screens are still useful in the assessment of vigabatrin induced visual field defects.
Topics: Adult; Anticonvulsants; Female; Humans; Vigabatrin; Vision Disorders; Visual Field Tests; Visual Fie | 2002 |
Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
Topics: Adult; Aged; Anticonvulsants; England; Female; Follow-Up Studies; Humans; Male; Medical Audit; Middl | 2002 |
Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Recovery of Function; Vigabatri | 2002 |
Patients treated with vigabatrin exhibit central visual function loss.
Topics: Adult; Anticonvulsants; Cohort Studies; Color Perception; Contrast Sensitivity; Discrimination, Psyc | 2002 |
Vigabatrin and visual field disorders.
Topics: Cohort Studies; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2002 |
[Constriction of the visual field by vigabatrin].
Topics: Anticonvulsants; Child; Epilepsy, Rolandic; Female; Humans; Vigabatrin; Vision Disorders; Visual Fie | 2002 |
Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Recovery of F | 2003 |
Field specific visual evoked potentials for assessment of peripheral field defect in a paediatric population.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Evoked Potentials, Visual; Female; Humans; Male; | 2000 |
Retinal function abnormalities in patients treated with vigabatrin.
Topics: Adolescent; Adult; Anticonvulsants; Color Perception Tests; Dark Adaptation; Electroretinography; Ep | 2003 |
Vigabatrin: longterm follow-up of electrophysiology and visual field examinations.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Electrooculography; Electroretinography; E | 2003 |
Sensorineural hearing loss: a reversible effect of vigabatrin.
Topics: Adolescent; Anticonvulsants; Audiometry; Epilepsies, Partial; Hearing Loss, Sensorineural; Humans; M | 2003 |
Visual field defects in pediatric patients on vigabatrin monotherapy.
Topics: Adolescent; Anticonvulsants; Automation; Child; Female; Humans; Male; Retrospective Studies; Vigabat | 2003 |
Examining visual field defects in the paediatric population exposed to vigabatrin.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroretinography; Evoked Potentials, Visual | 2003 |
Longitudinal changes in photopic OPs occurring with vigabatrin treatment.
Topics: Anticonvulsants; Child, Preschool; Electroretinography; Follow-Up Studies; Humans; Infant; Photic St | 2003 |
Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Middle Aged; Vigabatrin; | 2004 |
[Changes in visual field of a child treatment with vigabatrin for 2 years].
Topics: Anticonvulsants; Child; Drug Administration Schedule; Epilepsy; Humans; Male; Vigabatrin; Vision Dis | 2003 |
The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
Topics: Adult; Anticonvulsants; Female; Follow-Up Studies; Humans; Male; Middle Aged; Seizures; Vigabatrin; | 2005 |
Are vigabatrin-associated visual field constrictions asymptomatic?
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2004 |
Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA.
Topics: Acute Disease; Animals; Anticonvulsants; Darkness; gamma-Aminobutyric Acid; Light; Male; Nipecotic A | 2004 |
Visual field constriction associated with vigabatrin: retinal nerve fiber layer photographic correlation.
Topics: Adolescent; Anticonvulsants; Humans; Male; Nerve Fibers; Photography; Retina; Seizures; Vigabatrin; | 2004 |
Reduced visual function associated with infantile spasms in children on vigabatrin therapy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Contrast Sensitivity; Evoked Potentials | 2005 |
Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.
Topics: Adult; Anticonvulsants; Child; Epilepsy; Female; Functional Laterality; Humans; Male; Neurologic Exa | 2005 |
[Asymptomatic concentric visual field deficits and optic nerve atrophy].
Topics: Anticonvulsants; Humans; Male; Middle Aged; Optic Atrophy; Vigabatrin; Vision Disorders; Visual Fiel | 2006 |
The natural history of Vigabatrin-associated visual field defects in patients electing to continue their medication.
Topics: Anticonvulsants; England; Humans; Practice Guidelines as Topic; Vigabatrin; Vision Disorders; Vision | 2006 |
Visual defects associated with vigabatrin: a study of epileptic argentine patients.
Topics: Adult; Anticonvulsants; Argentina; Carbamazepine; Electroretinography; Epilepsy; Female; Humans; Mal | 2005 |
Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
Topics: Adult; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Nerv | 2006 |
[The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Epilepsies, Partial; Fe | 2005 |
Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Disabled Children; Epilepsy; Female; Humans; I | 2006 |
Vigabatrin and visual field defects in pediatric epilepsy patients.
Topics: Adult; Anticonvulsants; Child; Drug Monitoring; Drug Therapy, Combination; Epilepsy; Female; Humans; | 2006 |
Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss--could scanning laser polarimetry aid diagnosis?
Topics: Adult; Anticonvulsants; Diagnostic Techniques, Ophthalmological; Drug Administration Schedule; Femal | 2008 |
Vigabatrin and epilepsy: lessons learned.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Administrati | 2007 |
Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.
Topics: Adolescent; Adult; Aged; Algorithms; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Fe | 2008 |
Vigabatrin and epilepsy: further lessons in early childhood.
Topics: Age Factors; Anticonvulsants; Child; Child, Preschool; Cross-Cultural Comparison; Dose-Response Rela | 2008 |
Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
Topics: Adult; Aged; Anticonvulsants; Electroretinography; Epilepsy; Female; Humans; Male; Middle Aged; Reti | 2008 |
The ocular side effects of vigabatrin (Sabril): information and guidance for screening.
Topics: Anticonvulsants; Epilepsies, Partial; Female; Humans; Male; Vigabatrin; Vision Disorders; Vision Scr | 2008 |
Severe persistent visual field constriction associated with vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Male; | 1997 |
Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions.
Topics: Adult; Anticonvulsants; Chronic Disease; Epilepsy; gamma-Aminobutyric Acid; Humans; Male; Vigabatrin | 1997 |
Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Humans; Male; Vig | 1997 |
Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.
Topics: Adult; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Male; Vigabatrin; Vision Disorders; Vision | 1997 |
Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Vigabatrin; Vision Disorders; Visual Fields | 1997 |
Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Product Surveillance, Postmarketing; Vigabatrin; V | 1997 |
Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Risk Assessment; Vigabatrin; Vision Disorders; Vis | 1998 |
Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.
Topics: Adult; Anticonvulsants; Female; gamma-Aminobutyric Acid; Humans; Male; Vigabatrin; Vision Disorders; | 1998 |
Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.
Topics: Adult; Aged; Anticonvulsants; Electroretinography; Evoked Potentials, Visual; Female; gamma-Aminobut | 1998 |
Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.
Topics: Adolescent; Anticonvulsants; Electroretinography; Epilepsies, Partial; gamma-Aminobutyric Acid; Huma | 1998 |
Study is needed of visual field defects associated with any long term antiepileptic drug.
Topics: Anticoagulants; Enzyme Inhibitors; gamma-Aminobutyric Acid; Humans; Vigabatrin; Vision Disorders; Vi | 1998 |
Guideline may help in prescribing vigabatrin.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Guidelines as Topic; Humans; Vigabatrin; Vision Disorders | 1998 |
Vigabatrin-associated retinal cone system dysfunction.
Topics: Anticonvulsants; Electroretinography; gamma-Aminobutyric Acid; Humans; Retinal Cone Photoreceptor Ce | 1998 |
Vigabatrin-associated retinal cone system dysfunction.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Retinal Cone Photoreceptor Cells; Vigabatrin; Visi | 1998 |
Vigabatrin-associated retinal cone system dysfunction.
Topics: Anticonvulsants; gamma-Aminobutyric Acid; Humans; Retinal Cone Photoreceptor Cells; Vigabatrin; Visi | 1998 |
Infantile spasms and vigabatrin. Visual field defects may be permanent.
Topics: Adult; Anticonvulsants; Child; gamma-Aminobutyric Acid; Humans; Infant; Practice Guidelines as Topic | 1999 |
[Severe constriction of the visual field associated with vigabatrin discovered by thorough examination of a 17-year old girl].
Topics: Adolescent; Anticonvulsants; Epilepsies, Partial; Female; gamma-Aminobutyric Acid; Hemiplegia; Human | 1999 |
Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Electrooculography; Electroretinography; Enzym | 1999 |
Visual field defect associated with vigabatrin: observational cohort study.
Topics: Adult; Anticonvulsants; Cohort Studies; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Risk F | 1999 |
Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anticonvulsants; Color Perception; Electroence | 1999 |
Characteristics of a unique visual field defect attributed to vigabatrin.
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Male; Severity of Illne | 1999 |
Vigabatrin: an effective antiepilepsy drug--balancing the risk of visual dysfunction.
Topics: Anticonvulsants; Epilepsy; Humans; Risk Factors; Vigabatrin; Vision Disorders | 1999 |
A controlled study of vigabatrin and visual abnormalities.
Topics: Adult; Aged; Anticonvulsants; Case-Control Studies; Color Vision Defects; Dose-Response Relationship | 2000 |
Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
Topics: Anticonvulsants; Cross-Sectional Studies; Drug Resistance; Epilepsy, Temporal Lobe; Female; Humans; | 2000 |
Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.
Topics: Anticonvulsants; Epilepsy; Humans; Prevalence; Vigabatrin; Vision Disorders; Visual Fields | 2000 |
Visual field defect associated with vigabatrin. Method of estimating prevalence was inappropriate.
Topics: Anticonvulsants; Humans; Prevalence; Vigabatrin; Vision Disorders; Visual Fields | 2000 |
Visual field defect associated with vigabatrin. Means of selecting patients was misleading.
Topics: Adult; Anticonvulsants; Female; Humans; Patient Selection; Vigabatrin; Vision Disorders; Visual Fiel | 2000 |
Screening of patients taking vigabatrin.
Topics: Adolescent; Adult; Anticonvulsants; Child; Electrooculography; Electroretinography; Enzyme Inhibitor | 2000 |
Visual function loss from vigabatrin: effect of stopping the drug.
Topics: Adult; Aged; Color Perception; Electrooculography; Electroretinography; Epilepsy; Female; Humans; Ma | 2000 |
Visual impairment in children with epilepsy treated with vigabatrin.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Male; Retrospective | 2000 |
Vigabatrin-associated visual field defects in children.
Topics: Adolescent; Anticonvulsants; Child; Enzyme Inhibitors; Epilepsy; Female; Humans; Male; Retrospective | 2000 |
Visual field defects in patients taking vigabatrin.
Topics: Adult; Anticonvulsants; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Vigabatrin; Vision Dis | 2000 |
Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?
Topics: Adolescent; Anticonvulsants; Epilepsies, Partial; Female; Humans; Vigabatrin; Vision Disorders; Visu | 2000 |
Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.
Topics: Adult; Electrooculography; Electrophysiology; Electroretinography; Epilepsy; Evoked Potentials, Visu | 2000 |
Visual field defects associated with vigabratin monotherapy in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Vigabatrin; Vision Disorders | 2000 |
The role of vigabatrin in childhood seizure disorders: results from a clinical audit.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 2001 |
Visual field loss associated with vigabatrin: quantification and relation to dosage.
Topics: Adult; Ambulatory Care; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Sched | 2001 |
The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss.
Topics: Adult; Anticonvulsants; Electrooculography; Electroretinography; Epilepsy, Temporal Lobe; Humans; Mi | 2001 |
[Vigabatrin and visual fields defects].
Topics: Anticonvulsants; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2001 |
Vigabatrin visual toxicity: evolution and dose dependence.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Ag | 2001 |
Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina.
Topics: Animals; Anticonvulsants; Male; Nipecotic Acids; Rats; Rats, Sprague-Dawley; Retina; Tiagabine; Viga | 2001 |
Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
Topics: Adult; Aged; Anticonvulsants; Electroretinography; Humans; Middle Aged; Retinal Cone Photoreceptor C | 2001 |
Visual field constriction on vigabatrin.
Topics: Adult; Anticonvulsants; Epilepsy; Europe; Humans; Infant; Spasm; Treatment Outcome; Tuberous Scleros | 2000 |
Adverse events in medical management--vigabatrin as a paradigm of forensic responsibility with novel therapy.
Topics: Anticonvulsants; Decision Making; Epilepsy; Ethics, Medical; Humans; Informed Consent; Vigabatrin; V | 2001 |
Ethical dilemmas of potential adverse events.
Topics: Anticonvulsants; Epilepsy; Ethics, Medical; GABA Agonists; Humans; Informed Consent; Liability, Lega | 2001 |
GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects.
Topics: Anticonvulsants; Brain; Epilepsy; gamma-Aminobutyric Acid; Genomic Library; Humans; Ornithine-Oxo-Ac | 2001 |
[Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
Topics: Anticonvulsants; Epilepsy; Humans; Vigabatrin; Vision Disorders; Visual Fields | 2002 |
Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study.
Topics: Adult; Age Factors; Anticonvulsants; Epilepsy; Female; Humans; Longitudinal Studies; Male; Middle Ag | 2002 |
Effects of antiepileptic drugs on visual function, with special reference to Vigabatrin.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Color Perception; Epilepsy; Humans; Middle Aged; Vigabatri | 2002 |
Visual field constriction in 91 Finnish children treated with vigabatrin.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Disease Susceptibility; Dose-Resp | 2002 |